导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.24% | 1098/4773 |
| 近一周 | -0.69% | 1733/5467 |
| 近一月 | -5.99% | 2753/5421 |
| 近一季 | -9.96% | 3186/5238 |
| 近半年 | -1.43% | 1940/4931 |
| 近一年 | 10.48% | 1004/4400 |
| 近两年 | 84.91% | 762/2954 |
| 近三年 | 48.10% | 587/2253 |
| 成立以来 | 106.86% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.53% 902/4961 |
20.79% 1204/5312 |
- - |
- - |
| 2025 | 34.51% 1040/4813 |
2.60% 1313/3635 |
2.24% 1722/4076 |
26.07% 1367/4524 |
1.71% 1258/4813 |
| 2024 | 8.55% 1539/3463 |
-2.56% 1380/2808 |
-5.09% 1644/3014 |
17.11% 1275/3129 |
0.23% 1246/3463 |
| 2023 | -4.83% 694/2656 |
8.12% 495/2280 |
-3.93% 976/2385 |
-4.19% 1085/2515 |
-4.36% 980/2655 |
| 2022 | -17.92% 639/2207 |
-13.84% 853/1919 |
3.33% 1169/2016 |
-10.53% 420/2113 |
3.04% 779/2208 |
| 2021 | 22.55% 143/1822 |
-0.84% 398/1255 |
11.35% 380/1330 |
6.36% 228/1466 |
4.35% 338/1822 |
| 2020 | 28.68% 556/1250 |
-3.92% 329/1028 |
17.70% 364/1067 |
8.52% 709/1164 |
4.87% 826/1184 |
| 2019 | - - |
- - |
- - |
- - |
6.31% 629/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 博时中证500ETF VS. 长安沪深300非周期A(740101) |